SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently targeted by neutralizing antibodies (nAbs) in infected individuals. In chronic infection, HIV-1 escape mutants repopulate the plasma, and V3 and CD4bs nAbs emerge that can neutralize heterologous tier 1 easy-to-neutralize but not tier 2 difficult-to-neutralize HIV-1 isolates. However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has not been studied. We describe the development and evolution in vivo of antibodies distinguished by their target specificity for V3 and CD4bs epitopes on autologous tier 2 viruses but not on heterologous tier 2 viruses. A surprisingly high fraction of autologous circula...
emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling ...
Few studies have explored the role of neutralizing antibody (NAb) responses in controlling HIV-2 vir...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Approximately 1 % of those infected with HIV-1 develop broad and potent serum cross-neutralizing ant...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subse...
SummaryAntibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
Themonoclonal antibody (MAb) VRC01 was isolated from a slowly progressing HIV-1-infected donor and w...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
Author Summary Most HIV-1 infected individuals develop neutralizing antibodies against their own vir...
emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling ...
Few studies have explored the role of neutralizing antibody (NAb) responses in controlling HIV-2 vir...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Approximately 1 % of those infected with HIV-1 develop broad and potent serum cross-neutralizing ant...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subse...
SummaryAntibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
Themonoclonal antibody (MAb) VRC01 was isolated from a slowly progressing HIV-1-infected donor and w...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
Author Summary Most HIV-1 infected individuals develop neutralizing antibodies against their own vir...
emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling ...
Few studies have explored the role of neutralizing antibody (NAb) responses in controlling HIV-2 vir...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...